Concetta Quintarelli

Affiliated with

Research Area

Biography

Concetta Quintarelli has not added Biography.
If you are Concetta Quintarelli and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 2	Year
Publication title	2026
Publication title	2026

Other Publications

Article	Year
Preservation of Antigen-Specific Functions of αβ T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulati... Frontiers in immunology\| PubMed ID: 28386262	2017
NK Cell-Based Immunotherapy for Hematological Malignancies. Journal of clinical medicine\| PubMed ID: 31623224	2019
Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells. Frontiers in immunology\| PubMed ID: 31824502	2019
Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring. Journal of immunology research\| PubMed ID: 32322591	2020
Corrigendum to "Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring". Journal of immunology research\| PubMed ID: 32851098	2020
NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles. Seminars in hematology\| PubMed ID: 33256910	2020
The role of interferon-gamma and its signaling pathway in pediatric hematological disorders. Pediatric blood & cancer\| PubMed ID: 33484058	2021
GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape. Journal for immunotherapy of cancer\| PubMed ID: 33737337	2021
Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts. Journal for immunotherapy of cancer\| PubMed ID: 34135100	2021
Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We? Frontiers in immunology\| PubMed ID: 34163465	2021
PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches. Cancers\| PubMed ID: 34439194	2021
PD-1-induced T cell exhaustion is controlled by a Drp1-dependent mechanism. Molecular oncology\| PubMed ID: 34535949	2022
Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma. Journal of hematology & oncology\| PubMed ID: 34772439	2021
Nanoparticles for Diagnosis and Target Therapy in Pediatric Brain Cancers. Diagnostics (Basel, Switzerland)\| PubMed ID: 35054340	2022
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. Journal for immunotherapy of cancer\| PubMed ID: 35577500	2022
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML. Blood advances\| PubMed ID: 36037515	2022
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. Reply. The New England journal of medicine\| PubMed ID: 37314725	2023
Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Haematologica\| PubMed ID: 38832424	2024
Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study. Heliyon\| PubMed ID: 39713186	2024
Allogeneic CAR T cells: A new player in the field and the peculiar opportunities of the hospital exemption path. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 40414221	2025
International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML. Blood advances\| PubMed ID: 40829117	2025